Demand Breastfeeding in Infants using Diazoxide to Manage Congenital Hyperinsulinism
Authors' conclusion
Study findings support the feasibility and safety of demand breastfeeding in infants receiving diazoxide for CHI. This supports metabolic stability and parental feeding goals.
Study context
- Population
- Infants with biochemically confirmed congenital hyperinsulinism receiving diazoxide; 13 males and 4 females; 2 with genetic congenital hyperinsulinism (CHI) (ABCC8, HNF4A variants), the rest transient CHI
- Participants
- 17 infants
- Outcome
- Safe glycaemic stability without risk of fluid overload with demand breastfeeding during diazoxide therapy
Main finding
As reported in the abstract
throughout treatment period
All infants were demand breastfed
17
Transitioned from restricted bottle-feeding to successful demand breastfeeding during treatment
4
Observational data: associations, not effects.
Further findings
Duration of diazoxide therapy
- Transient CHI: duration range
- 5 to 13 weeks
- Genetic CHI (2 patients): prolonged therapy, duration at time of study
- 9-18 months
Safety
- No diazoxide-related adverse effects observed
- Therapy did not interfere with breastfeeding progression
Original publication
Demand Breastfeeding in Infants using Diazoxide to Manage Congenital Hyperinsulinism. Horm Res Paediatr. Published 12 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →